EGFR and undifferentiated pleomorphic sarcoma: Amplifications and activating mutations of PDGFRA, PDGFRB, and EGFR have been reported in cardiac and rare intracranial UPS, providing a rationale for exploring therapies targeting PDGF receptors and EGFR [28,29].